Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Linical Co., Ltd. ( (JP:2183) ) just unveiled an announcement.
Linical Co., Ltd. reported that it booked significant impairment losses in the fourth quarter of the year ended March 2026, reflecting continued severe business conditions in its Japanese and European operations, where project cancellations and delays have weighed on profitability. The company recognized a total of ¥989 million in impairment on fixed assets and goodwill at the consolidated level and an additional ¥161 million fixed-asset impairment on a non-consolidated basis, while also cutting personnel in Europe, restricting hiring in Japan, and selectively adding sales staff to reinforce its global structure.
Separately, Linical recorded a ¥1,333 million loss on valuation of shares in its German affiliate LINICAL Holding GmbH in its non-consolidated accounts under Japanese GAAP, though this charge is eliminated at the consolidated level and does not affect group results. Full-year consolidated sales of ¥8,665 million were essentially in line with the prior forecast and slightly above the previous year’s operating and ordinary profit projections due to cost controls, but net profit attributable to owners of the parent missed guidance, falling to a ¥3,329 million loss mainly because of the extraordinary impairment, underscoring the financial strain from its underperforming assets and challenging market environment.
More about Linical Co., Ltd.
Linical Co., Ltd. is a Japan-based contract research organization (CRO) listed on the Tokyo Stock Exchange that provides clinical trial and related development services to pharmaceutical and biotech companies. The company operates globally, including in Japan and Europe, and focuses on supporting large-scale clinical projects while managing its cost base and staffing to adapt to changing demand conditions.
Average Trading Volume: 42,324
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen5.42B
For a thorough assessment of 2183 stock, go to TipRanks’ Stock Analysis page.